• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sight Sciences Inc. (Amendment)

    2/14/23 4:06:29 PM ET
    $SGHT
    Medical/Dental Instruments
    Health Care
    Get the next $SGHT alert in real time by email
    SC 13G/A 1 d412718dsc13ga.htm SC 13G/A SC 13G/A

     

     

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G/A

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

     

     

    Sight Sciences, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    82657M105

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☐

    Rule 13d-1(c)

     

    ☒

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


      1    

      Names of Reporting Persons

     

      Paul Badawi

      2  

      Check the Appropriate Box if a Member of a Group

     

      (a)  ☐        (b)  ☐

      3  

      SEC Use Only

     

      4  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5     

      Sole Voting Power

     

      5,691,953(1)

       6   

      Shared Voting Power

     

      0

       7   

      Sole Dispositive Power

     

      5,691,953(1)

       8   

      Shared Dispositive Power

     

      0

      9    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      5,691,953(1)

    10  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares  ☐

     

      Not Applicable

    11  

      Percent of Class Represented by Amount in Row 9

     

      11.8%(2)

    12  

      Type of Reporting Person

     

      IN

     

    (1)

    The Reporting Person is the beneficial owner of 5,691,953 shares of Common Stock, of which (i) 5,264,782 shares of Common Stock are held by the Reporting Person as of December 31, 2022, (ii) 21,950 shares of common stock that will be issued upon the settlement of restricted stock units on January 1, 2023, and (iii) 405,221 shares of Common Stock underlying stock options that are exercisable prior to March 1, 2023.

    (2)

    Based upon 48,151,302 shares of Common Stock outstanding as of November 4, 2022, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, that was filed with the Securities and Exchange Commission on November 10, 2022.


    ITEM 1. (a)

    Name of Issuer:

    Sight Sciences, Inc. (the “Issuer”).

    (b) Address of Issuer’s Principal Executive Offices:

    4040 Campbell Ave, Suite 100, Menlo Park, California 94025

     

    ITEM 2. (a)

    Name of Person Filing:

    This statement is filed on behalf of Paul Badawi (the “Reporting Person”).

    (b) Address or Principal Business Office:

    The business address of the Reporting Person is c/o Sight Sciences, Inc., 4040 Campbell Ave, Suite 100, Menlo Park, California 94025.

    (c) Citizenship of each Reporting Person is:

    Paul Badawi is a citizen of the United States.

    (d) Title of Class of Securities:

    Common Stock, par value $0.001 per share (“Common Stock”).

    (e) CUSIP Number:

    82657M105

     

    ITEM 3.

    Not applicable.

     

    ITEM 4.

    Ownership.

    (a-c)

     

    Reporting Person   

    Amount

    beneficially

    owned

       

    Percent

    of class:

        Sole power
    to vote or to
    direct the
    vote:
        Shared power
    to vote or to
    direct the vote:
        

    Sole

    power to

    dispose or
    to direct
    the

    disposition

    of:

       

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     

    Paul Badawi

         5,691,953 (1)      11.8 %(2)      5,691,953 (1)      0        5,691,953 (1)      0  

     

    (1)

    The Reporting Person is the beneficial owner of 5,691,953 shares of Common Stock, of which (i) 5,264,782 shares of Common Stock are held by the Reporting Person as of December 31, 2022, (ii) 21,950 shares of common stock that will be issued upon the settlement of restricted stock units on January 1, 2023, and (iii) 405,221 shares of Common Stock underlying stock options that are exercisable prior to March 1, 2023.

    (2)

    Based upon 48,151,302 shares of Common Stock outstanding as of November 4, 2022, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, that was filed with the Securities and Exchange Commission on November 10, 2022.


    ITEM 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    ITEM 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    ITEM 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

     

    ITEM 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    ITEM 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    ITEM 10.

    Certification.

    Not applicable.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 14, 2023

     

    Paul Badawi
    /s/ Paul Badawi
    Get the next $SGHT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SGHT

    DatePrice TargetRatingAnalyst
    12/6/2024$5.50Buy
    UBS
    11/4/2024$10.00 → $5.00Buy → Hold
    Lake Street
    8/21/2024$10.00Buy
    Lake Street
    9/12/2023$10.00 → $4.50Neutral → Underperform
    BofA Securities
    9/12/2023$15.00 → $5.50Overweight → Neutral
    Piper Sandler
    9/12/2023Outperform → Mkt Perform
    William Blair
    8/24/2023$12.00 → $8.40Overweight → Equal-Weight
    Morgan Stanley
    7/10/2023$15.00 → $9.00Buy → Neutral
    Citigroup
    More analyst ratings

    $SGHT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sight Sciences Inc.

      SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

      11/14/24 11:57:36 AM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Sight Sciences Inc. (Amendment)

      SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

      2/14/24 5:24:02 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Sight Sciences Inc.

      SC 13G - Sight Sciences, Inc. (0001531177) (Subject)

      2/13/24 6:52:37 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    SEC Filings

    See more
    • SEC Form SD filed by Sight Sciences Inc.

      SD - Sight Sciences, Inc. (0001531177) (Filer)

      5/30/25 4:35:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Sight Sciences Inc.

      10-Q - Sight Sciences, Inc. (0001531177) (Filer)

      5/8/25 4:16:05 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Sight Sciences, Inc. (0001531177) (Filer)

      5/8/25 4:08:25 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Sight Sciences with a new price target

      UBS initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $5.50

      12/6/24 8:14:13 AM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences downgraded by Lake Street with a new price target

      Lake Street downgraded Sight Sciences from Buy to Hold and set a new price target of $5.00 from $10.00 previously

      11/4/24 8:26:06 AM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Sight Sciences with a new price target

      Lake Street initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $10.00

      8/21/24 8:27:48 AM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th

      MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the Stifel 2025 Virtual Ophthalmology Forum. Sight Sciences' management is scheduled to present on Tuesday, May 27, 2025, at 09:00 am PT / 12:00 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the Investors section of the Company's website at https://investors.sightsciences.com/. About Sight Sciences Sight Sciences is an eyecar

      5/14/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

      MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025.   Recent Financial and Business Highlights Generated first quarter 2025 total revenue of $17.5 million, a decrease of 9% compared to the same period in the prior year. This decline was primarily due to lower revenue from the Company's

      5/8/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

      MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2025, after the market close on Thursday, May 8, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at

      4/24/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Encrantz Staffan bought $451,734 worth of shares (128,189 units at $3.52), increasing direct ownership by 12% to 1,157,705 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/29/25 9:31:17 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • EVP, Research & Development Raheja Manohar K. was granted 12,767 shares, increasing direct ownership by 8% to 167,767 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/21/25 8:39:13 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Bauerlein Alison sold $45,430 worth of shares (13,066 units at $3.48), decreasing direct ownership by 2% to 636,728 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/21/25 8:38:03 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Encrantz Staffan bought $451,734 worth of shares (128,189 units at $3.52), increasing direct ownership by 12% to 1,157,705 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/29/25 9:31:17 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • EVP, Research & Development Raheja Manohar K. bought $53,250 worth of shares (20,000 units at $2.66) and was granted 24,000 shares, increasing direct ownership by 40% to 155,000 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      3/13/25 9:51:29 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • EVP, Research & Development Raheja Manohar K. bought $19,250 worth of shares (5,000 units at $3.85), increasing direct ownership by 5% to 111,000 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      12/9/24 6:16:25 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Financials

    Live finance-specific insights

    See more
    • Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

      MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025.   Recent Financial and Business Highlights Generated first quarter 2025 total revenue of $17.5 million, a decrease of 9% compared to the same period in the prior year. This decline was primarily due to lower revenue from the Company's

      5/8/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

      MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2025, after the market close on Thursday, May 8, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at

      4/24/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance

      MENLO PARK, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the fourth quarter and full year ended December 31, 2024 and initiated financial guidance for full year 2025. Recent Financial Highlights Generated fourth quarter 2024 total revenue of $19.1 million, an increase of 2% compared to the same period in the prior year, and full year 2024 total revenue of $79.9 million, a decrease of 1% compared to full year 2023.Achieved total gross marg

      3/5/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Leadership Updates

    Live Leadership Updates

    See more
    • Sight Sciences Appoints Gary Burbach to its Board of Directors

      MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. "We are very excited to add Gary to our Board of Directors," stated Paul Badawi, Co-founder and Chief Executive Officer of Sight Sciences. "He brings a strong medtech industry background with a pro

      4/22/25 4:05:00 PM ET
      $BWXT
      $SGHT
      Industrial Machinery/Components
      Industrials
      Medical/Dental Instruments
      Health Care
    • Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

      MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con

      11/7/24 4:04:00 PM ET
      $INGN
      $SGHT
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Sight Sciences Appoints Matt Link as Chief Commercial Officer

      MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced the appointment of Matthew Link as its Chief Commercial Officer, effective September 11, 2023. "We are very excited to have Matt join Sight Sciences as we scale our Surgical Glaucoma and Dry Eye businesses. Matt is a highly talented medtech business leader with a track record of success in transforming treatment paradigms with disruptive new technology, and predictably scaling in a public high-growth

      9/11/23 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care